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The global COVID-19 pandemic has prompted urgent need for potential therapies for 
severe respiratory consequences resulting from coronavirus infection.  New therapeutic 
agents that will attenuate ongoing inflammation and at the same time promote 
regeneration of injured lung epithelial cells are urgently needed. Cell-based therapies, 
primarily involving mesenchymal stromal cells (MSCs) and their derivatives are currently 
being investigated worldwide for SARS-CoV-2-induced lung diseases. A significant number 
of academic centers and companies globally have already initiated such trials.  However, at 
a time of unprecedented need, it is also foreseen that families and caregivers will seek all 
available options including access to cell-based and other investigational products, even 
prior to proven safety and efficacy as well as regulatory approval.  This should not be an 
excuse for opportunists to sell or advertise unproven therapies of any kind.  
“Compassionate use” should be conducted in the context of a clinical investigation framed 
by strict ethical and regulatory permissions, with the goal of obtaining mechanistic 



































































































































































































































































The serious consequences of the COVID-19 pandemic have prompted a global initiative to 
develop effective therapies that can lessen disease severity in infected patients, 
particularly those with severe respiratory disease. Cell-based approaches, primarily using 
mesenchymal stromal cells (MSCs), have demonstrated an acceptable safety profile in 
patients with non-SARS-CoV-2 related acute respiratory distress syndrome (ARDS) in the 
limited currently available information.1 However, whether these therapies are effective 
for treating respiratory virus-induced ARDS, including that resulting from SARS-CoV-2, is 
unknown.[1] This is despite several recent case reports and uncontrolled case series 
suggesting potential efficacy.[2,3]  Regardless, there are an increasing number of both 
academic and industry-sponsored trials of cell-based therapies for COVID-19 patients 
initiated over the past several months.  Most are investigating use of MSCs, but some are 
investigating MSC-derived products including extracellular vesicles (EVs) and some are 
utilizing other cell types. In parallel, there has been a worrisome increase in the number of 
businesses offering unproven and untested cell-based therapy approaches in uncontrolled 
and unregulated settings.[4]  This creates a potentially dangerous situation for patients, 
families, and care-givers in often desperate situations.  
An overview of the rationale, pre-clinical data, and clinical experience of cell-based 
therapy in non-COVID-related ARDS provides a strong platform underlying legitimate 
investigations.  There is a wealth of pre-clinical data in both small and large animal models 
as well as in explanted human lungs in which either systemic or direct airway 
administration of MSCs mitigates experimentally-induced acute lung injuries resulting from 
bacteria or bacterial product, for example gram-negative bacterial endotoxin, 
administration.[5,6]   The postulated mechanisms largely focus on paracrine actions of the 
administered MSCs including release of anti-inflammatory cytokines, anti-bacterial 
peptides, and extracellular vesicles that mitigate inflammation in the setting of acute lung 
injuries (Figure 1).[7]   These encouraging results have provided a basis for the growing 
number of academic and industry-sponsored investigations of systemically administered 
MSCs in (non-COVID) ARDS patients.[1]  While these studies have uniformly demonstrated 
a good safety profile, there remains uncertainty about potential efficacy. One major 
academic-based trial did not demonstrate clinical efficacy[8], whereas improvement in 


































































































































































































































































decreased one month mortality, was suggested in one major industry trial.[9]  However, 
neither of these trials have specifically targeted patients with respiratory virus-induced 
ARDS.  Further, there are only a small number of pre-clinical studies in models of 
respiratory virus infection and these all involve influenza rather than coronavirus.  Notably, 
there were contrasting results of efficacy in these studies, possibly related to the type of 
influenza (swine vs. avian) infection utilized.  This furthers adds to uncertainty about 
whether MSC or other cell or cell product administration will have specific efficacy in SARS-
CoV-2 induced respiratory failure. There is almost no available clinical data with respect to 
MSC administration in other types of respiratory virus infections with only a case report in 
a patient with H1N1 flu-related ARDS (allogeneic bone marrow-derived MSCs)[10] and a 
case series following H7N9 flu infection (allogeneic menstrual blood-derived MSCs).[11] 
A recent search (November, 2020) of the NIH clinical trial database and the World Health 
Organization-International Clinical Trial Registry Platform (WHO-ICTRP) revealed over 
3,787 recently registered clinical trials for COVID-19.  Among these are 154 cell and gene 
therapy-based trials worldwide, with most registered in China (41) and the  the USA (36). 
Most of these utilize MSCs or their secreted products, including EVs or conditioned media. 
In a previous comprehensive review, we had presented an exhaustive summary of ongoing 
studies registered in the Chinese Clinical Trial Registry (chictr.org.cn) also accessible from 
the World Health Organization-International Clinical Trial Registry Platform (WHO-
ICTRP).[1] Following the continued spread of the pandemic, we complement that 
information with an updated list of trials with investigational new drug (IND) clearance 
from the US.FDA (Table 1).  Notably, a wide range of protocols with allogeneic MSCs of 
different origins, different doses, and different dosing strategies are being utilized. The 
dose of injected cells ranges from 0.5 to 2 x 106 cells/kg or the equivalent in a predefined 
infusion dose. The number of injections varies between a single dose and up to three 
doses separated between 3- 5 days with one trial utilizing up to 4 separate doses. .  
Importantly, there is also a wide range of patient groups being targeted including those 
with mild or moderate disease in addition to those with severe disease. A variety of 
enrollment designs are being utilized including emergency and compassionate use, with 
only a small proportion of trials using a randomized, double-blinded placebo control 


































































































































































































































































in 3 registered trials. It is unclear whether the cells were obtained previous to infection 
through adult stem cell banking or harvested after infection. In two trials, MSC are being 
used as prophylaxis not only in asymptomatic COVID-19 patients but also in healthy 
individuals at high or very high exposure risk of contracting COVID-19. While the majority 
of investigations are utilizing modified MSCs, one industry trial is evaluating the safety and 
feasibility of MSCs RNA-engineered to secrete a combination of DNases (Table 1).  Further, 
although there is a less robust mechanistic and pre-clinical platform, at least seven 
investigations are utilizing other cell types including, among others, cytotoxic T cells (CTL), 
dendritic cells (DC), primary natural killer cells (NK) and  induced pluripotent stem cell 
(iPSC)-derived NK cells already being used to treat cancer patients [12].  There is a paucity 
of direct evidence for the protective or pathological role of NK cells in the response to 
SARS-Cov-2 infection. In the context of non-respiratory viral infections by human 
immunodeficiency virus (HIV) and hepatitis C virus (HCV), NK cells appear to prevent T cell-
mediated autoimmunity through their cytotoxic  properties [13]. However, NK cells are 
one of the main producers of the pro-inflammatory mediator IFN-γ, hence, they may be 
involved in the induction or perpetuation of inflammation-mediated lung injuries, and 
subsequent mortality associated with COVID-19 [14].   
Despite the lack of preclinical information in COVID-19 or any other respiratory virus 
pathophysiology, there has been clearance by the FDA of an investigational new drug (IND) 
application for the use of NK cells in clinical testing.[15] Whether these approaches are 
even safe for COVID-19 patients has yet to be clarified.  As such we urge the FDA and other 
regulatory agencies to take a careful position with respect to approving cell-based 
products with unclear track records in either pre-clinical or clinical studies in lung diseases 
or critical illnesses for use in COVID 19 patients. 
Convalescent T-cells isolated from COVID-19 patients are also being considered. Recently, 
SARS-CoV-2 -specific T-cells were shown to be polyfunctional and can be expanded from 
convalescent individuals. These T-cell were able to target structural viral proteins, 
including the C-terminus of membrane protein, making them good candidate for the 
prevention or early treatment of SARS-CoV-2 infection in immunocompromised patients 
with blood disorders [16]. 


































































































































































































































































Of the recent published reports and small case series from both academic and industry 
sources suggesting potential efficacy of systemic MSC administration in COVID-19 patients, 
the available data presented is either anecdotal or from incompletely presented, poorly 
controlled investigations.[2,17]  The situation is also further complicated by lack of 
consensus or full understanding with respect to MSC source of origin, dose, dosing 
strategy, use of freshly thawed vs. continuously cultured cells, and other factors involved 
in potential use of MSC-based cell therapies.  The same holds for a recent published initial 
safety investigation utilizing MSC-derived EVs in which no information about the actual 
biological substance being administered was provided.[18] Therefore, while there may be 
a potential role for MSCs and other cell-based therapies in treatment of COVID-19, these 
need to be investigated in a rationally designed, controlled approach if safety and efficacy 
are to be demonstrated accurately.  Importantly, in addition to legitimate peer-reviewed 
academic trials being conducted globally, one industry-sponsored prospective randomized, 
double blinded, placebo-controlled phase II  ( intramuscular injection of Placental-MSC, 
ClinicalTrials.gov Identifiers: NCT04389450) and  two phase III trials of intravenously 
administered marrow-derived MSC-like products for severe COVID-19 have been initiated 
in the USA (NCT04367077 and NCT04371393). The hope is these and comparable studies 
will provide robust data informing the utility of systemic MSC administration for COVID-
related ARDS (Table 1). 
At a time of unprecedented need, it is natural for patients, families, and caregivers to seek 
all available options including access to cell-based and other investigational products, even 
prior to adequate demonstration of safety and efficacy and according regulatory approval.  
This should not be an excuse for opportunists to sell or advertise unproven therapies of 
any kind.  “Compassionate use” should be conducted in the context of a clinical 
investigation framed by strict ethical and regulatory permissions, such as expanded access 
authorization, with the goal of obtaining mechanistic information wherever possible.  
There must be a strong stance against the rogue stem-cell clinic industry which has already 
begun to offer unproven therapies for COVID-19. A number of global organizations, 
including the International Society for Cell and Gene Therapy (ISCT) and the International 
Society for Stem Cell Research (ISSCR), have taken positions against this predatory 


































































































































































































































































offering unproven therapies, but more regulatory oversight and action are needed.[20] 
These actions are necessary to develop rationale evidence-based platform for potential 
use of cell-based therapies both for COVID-19 but also for a wider range of respiratory and 
other diseases potentially amenable to these advanced therapies. 
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  Table 1: US-FDA approved MSC-based clinical trials for COVID-19 
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UC-MSCs, Umbilical cord derived-mesenchymal stem cells; BM-MSCs, bone marrow 




































































































































































































































































Figure 1: Overview of MSC properties relevant for potential use in COVID-19 related severe 
respiratory disease. 
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